BioMarin Pharmaceutical Inc (BioMarin) develops products for unmet medical needs. The company reports its operations through single segment: Development and Commercialization of Innovative therapies for People with Serious and Life-Threatening Rare Diseases and Medical Conditions.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

BioMarin's pipeline products, if commercialized successfully, could expand its product portfolio and increase its revenue. Its major products under development include Vosoritide in Phase III clinical trial for the treatment of achondroplasia; BMN 270 in Phase I clinical trial for the treatment of hemophilia A; and BMN 307 in pre clinical testing for the treatment of phenylketonuria (PKU). In FY2022, the company spent US$649.6 million on its R&D, which as a percentage of revenue stood at 31%. The company's R&D division had 736 employees as of December 31, 2022.